985 Shares in argenex SE (NASDAQ:ARGX) Bought by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. acquired a new stake in argenex SE (NASDAQ:ARGX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 985 shares of the company's stock, valued at approximately $583,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ARGX. GeoWealth Management LLC increased its stake in shares of argenex by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after purchasing an additional 18 shares during the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of argenex by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock worth $234,000 after purchasing an additional 20 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of argenex by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after purchasing an additional 21 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of argenex by 56.4% during the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after purchasing an additional 22 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in argenex by 23.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 121 shares of the company's stock worth $74,000 after buying an additional 23 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenex Stock Down 0.5%

Shares of NASDAQ ARGX traded down $3.07 during mid-day trading on Friday, reaching $560.24. 248,404 shares of the company were exchanged, compared to its average volume of 333,066. argenex SE has a 52 week low of $457.42 and a 52 week high of $678.21. The stock has a market capitalization of $34.21 billion, a PE ratio of 34.56, a PEG ratio of 1.03 and a beta of 0.37. The company's 50 day moving average price is $567.54 and its 200 day moving average price is $601.83.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million. On average, sell-side analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 price objective on shares of argenex in a report on Tuesday, July 1st. Deutsche Bank Aktiengesellschaft raised shares of argenex from a "hold" rating to a "buy" rating in a report on Tuesday. Sanford C. Bernstein raised shares of argenex from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Guggenheim cut their price objective on shares of argenex from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Nineteen research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $728.06.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.